By James Hudson - January 7, 2019
 

Shares of Generex Biotechnology Corporation (OTCMKTS:GNBT) have been ripping higher over recent days. To further flesh out the story, the company just announced that it has completed the acquisition of 51% of Regentys Corporation, a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders.

According to the release, “The terms of the deal include the previously reported upfront payment of $400,000, plus $14.6 million to be paid according to a milestone-based schedule. Details of the transaction can be found in the Generex 8K filing with the SEC.”

Shares of Generex Biotechnology Corporation (OTCMKTS:GNBT) have been ripping higher over recent days. To further flesh out the story, the company just announced that it has completed the acquisition of 51% of Regentys Corporation, a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders.

According to the release, “The terms of the deal include the previously reported upfront payment of $400,000, plus $14.6 million to be paid according to a milestone-based schedule. Details of the transaction can be found in the Generex 8K filing with the SEC.”

As noted above, GNBT just announced that it has completed the acquisition of 51% of Regentys Corporation, a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders.

Recent action has seen 55% piled on for shareholders of the listing during the trailing week. What’s more, the stock has witnessed a pop in interest, as transaction volume levels have recently pushed 72% beyond what we have been seeing over the larger time frame.

Joe Moscato, CEO of Generex commented on the acquisition, “The completion of this Regentys acquisition demonstrates our commitment to build a world-class regenerative medicine business by acquiring great companies with cutting-edge, patented technologies and exceptional management teams. Our direct investment in the clinical development of Regentys ECMH will provide long-term value to Generex investors as we achieve milestones on the path to commercialization in the billion dollar markets for ulcerative colitis and other inflammatory bowel diseases.”

Currently trading at a market capitalization of $94.05M, GNBT has a chunk ($2.4M) of cash on the books, which stands against about $42.9M in total current liabilities. One should also note that debt has been growing over recent quarters. GNBT is pulling in trailing 12-month revenues of $2.4M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 77408.9%. We will update the story again soon as developments transpire. Sign-up for continuing coverage on shares of $GNBT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $GNBT, either long or short, and we have not been compensated for this article.

Oracle has also recently published articles on Potnetworks (POTN),  Charlotte's Web Holdings (CWBHF),  and  Terra Tech Corp (TRTC).

Original Source: https://oracledispatch.com/2019/01/07/generex-biotechnology-corporation-otcmktsgnbt-shares-just-caught-fire/

Charlottes Web (QX) (USOTC:CWBHF)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Charlottes Web (QX) Charts.
Charlottes Web (QX) (USOTC:CWBHF)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Charlottes Web (QX) Charts.